Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CFO Sells $3,389,921.28 in Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CFO Mark Ragosa sold 36,783 shares of the stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $92.16, for a total value of $3,389,921.28. Following the sale, the chief financial officer owned 20,854 shares in the company, valued at approximately $1,921,904.64. This represents a 63.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Trading Down 8.1%

Kiniksa Pharmaceuticals International stock opened at $88.34 on Friday. Kiniksa Pharmaceuticals International, plc has a 12 month low of $37.02 and a 12 month high of $98.48. The stock has a fifty day simple moving average of $80.18 and a two-hundred day simple moving average of $61.10. The firm has a market cap of $6.89 billion, a price-to-earnings ratio of 67.95 and a beta of 0.07.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19. The firm had revenue of $285.97 million for the quarter, compared to the consensus estimate of $260.66 million. Kiniksa Pharmaceuticals International had a return on equity of 17.27% and a net margin of 11.58%. On average, equities research analysts forecast that Kiniksa Pharmaceuticals International, plc will post 1.30 EPS for the current fiscal year.

Analysts Set New Price Targets

KNSA has been the topic of several research analyst reports. Weiss Ratings cut shares of Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c-)” rating in a research note on Wednesday, October 28th. Wells Fargo & Company lifted their price target on shares of Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 28th. Wedbush boosted their price objective on shares of Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the company an “outperform” rating in a report on Wednesday, October 28th. The Goldman Sachs Group boosted their price objective on shares of Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the company a “buy” rating in a report on Wednesday, October 28th. Finally, Canaccord Genuity Group increased their price objective on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $100.57.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

A number of institutional investors and hedge funds have recently modified their holdings of the company. Headlands Technologies LLC bought a new stake in shares of Kiniksa Pharmaceuticals International in the second quarter worth $1,161,000. OMERS ADMINISTRATION Corp bought a new position in Kiniksa Pharmaceuticals International in the first quarter valued at about $631,000. Handelsbanken Fonder AB bought a new position in Kiniksa Pharmaceuticals International in the second quarter valued at about $1,343,000. The Manufacturers Life Insurance Company lifted its holdings in Kiniksa Pharmaceuticals International by 56.7% in the first quarter. The Manufacturers Life Insurance Company now owns 63,346 shares of the company’s stock valued at $3,050,000 after acquiring an additional 22,917 shares during the period. Finally, Janus Henderson Group PLC lifted its holdings in Kiniksa Pharmaceuticals International by 213.5% in the first quarter. Janus Henderson Group PLC now owns 481,023 shares of the company’s stock valued at $23,197,000 after acquiring an additional 327,595 shares during the period. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.